 Jean Mulcahy Levy
Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proto-Oncogene Proteins B-raf | 8 | 2025 | 225 | 3.130 |
Why?
| | Glioma | 11 | 2025 | 425 | 2.620 |
Why?
| | Brain Neoplasms | 16 | 2025 | 1318 | 2.590 |
Why?
| | Autophagy | 8 | 2021 | 286 | 2.180 |
Why?
| | Central Nervous System Neoplasms | 3 | 2019 | 173 | 1.350 |
Why?
| | Ganglioglioma | 1 | 2025 | 34 | 0.890 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 732 | 0.660 |
Why?
| | Chloroquine | 3 | 2017 | 53 | 0.630 |
Why?
| | Ependymoma | 4 | 2026 | 176 | 0.540 |
Why?
| | Transplantation, Autologous | 1 | 2019 | 290 | 0.540 |
Why?
| | Mutation | 8 | 2025 | 4089 | 0.520 |
Why?
| | Chordoma | 1 | 2017 | 17 | 0.510 |
Why?
| | Skull Base Neoplasms | 1 | 2017 | 30 | 0.510 |
Why?
| | Tuberous Sclerosis | 1 | 2017 | 56 | 0.490 |
Why?
| | Protein Kinase Inhibitors | 4 | 2025 | 969 | 0.460 |
Why?
| | Indoles | 2 | 2017 | 501 | 0.450 |
Why?
| | Sulfonamides | 2 | 2017 | 580 | 0.450 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2025 | 881 | 0.440 |
Why?
| | Epilepsy | 1 | 2018 | 376 | 0.410 |
Why?
| | Neoplasms | 3 | 2025 | 2875 | 0.400 |
Why?
| | Tumor Suppressor Proteins | 3 | 2021 | 321 | 0.370 |
Why?
| | Whole-Body Irradiation | 1 | 2012 | 76 | 0.360 |
Why?
| | Antineoplastic Agents | 4 | 2017 | 2194 | 0.340 |
Why?
| | Child, Preschool | 12 | 2026 | 11787 | 0.340 |
Why?
| | Child | 18 | 2026 | 22633 | 0.330 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2017 | 675 | 0.330 |
Why?
| | Biomarkers, Tumor | 4 | 2024 | 1313 | 0.320 |
Why?
| | Survivors | 2 | 2023 | 520 | 0.320 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 210 | 0.290 |
Why?
| | Cell Line, Tumor | 7 | 2025 | 3540 | 0.260 |
Why?
| | Humans | 35 | 2026 | 144759 | 0.260 |
Why?
| | Cell Survival | 3 | 2019 | 1098 | 0.240 |
Why?
| | RNA-Binding Proteins | 2 | 2021 | 462 | 0.240 |
Why?
| | Infant | 8 | 2026 | 10034 | 0.230 |
Why?
| | Trastuzumab | 1 | 2026 | 118 | 0.230 |
Why?
| | Infratentorial Neoplasms | 1 | 2026 | 71 | 0.230 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2026 | 161 | 0.220 |
Why?
| | Adolescent | 11 | 2025 | 22428 | 0.220 |
Why?
| | Cerebellar Neoplasms | 2 | 2018 | 177 | 0.220 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2025 | 128 | 0.220 |
Why?
| | Medulloblastoma | 2 | 2018 | 215 | 0.220 |
Why?
| | Hydrocephalus | 1 | 2025 | 111 | 0.210 |
Why?
| | Astrocytoma | 1 | 2025 | 129 | 0.210 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2024 | 54 | 0.210 |
Why?
| | Pyrimidinones | 1 | 2025 | 126 | 0.210 |
Why?
| | Retinal Diseases | 1 | 2025 | 101 | 0.210 |
Why?
| | Pyridones | 1 | 2025 | 199 | 0.190 |
Why?
| | Male | 18 | 2026 | 72315 | 0.190 |
Why?
| | STAT3 Transcription Factor | 2 | 2015 | 207 | 0.190 |
Why?
| | raf Kinases | 1 | 2021 | 11 | 0.180 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1053 | 0.180 |
Why?
| | Radiation | 1 | 2021 | 24 | 0.170 |
Why?
| | Transcriptome | 2 | 2025 | 1045 | 0.170 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2021 | 68 | 0.170 |
Why?
| | Pituitary Diseases | 1 | 2020 | 20 | 0.170 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2020 | 36 | 0.160 |
Why?
| | Pituitary Gland | 1 | 2020 | 148 | 0.160 |
Why?
| | Immunocompromised Host | 1 | 2021 | 201 | 0.150 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2019 | 14 | 0.150 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 310 | 0.150 |
Why?
| | Biological Assay | 2 | 2021 | 128 | 0.150 |
Why?
| | N-Myc Proto-Oncogene Protein | 1 | 2019 | 11 | 0.150 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2019 | 26 | 0.150 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2026 | 1137 | 0.150 |
Why?
| | Female | 15 | 2026 | 78271 | 0.150 |
Why?
| | Aminopyridines | 1 | 2019 | 127 | 0.140 |
Why?
| | Prognosis | 4 | 2026 | 4282 | 0.140 |
Why?
| | Multigene Family | 1 | 2019 | 204 | 0.140 |
Why?
| | Sepsis | 1 | 2025 | 640 | 0.140 |
Why?
| | Benzamides | 1 | 2019 | 224 | 0.140 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 75 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2026 | 1953 | 0.140 |
Why?
| | Skull Neoplasms | 1 | 2017 | 21 | 0.140 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2017 | 29 | 0.130 |
Why?
| | Rhabdomyoma | 1 | 2017 | 7 | 0.130 |
Why?
| | Angiomyolipoma | 1 | 2017 | 21 | 0.130 |
Why?
| | Blotting, Western | 1 | 2019 | 1187 | 0.130 |
Why?
| | Heart Neoplasms | 1 | 2017 | 55 | 0.120 |
Why?
| | Electric Stimulation Therapy | 1 | 2017 | 62 | 0.120 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 432 | 0.120 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 27 | 0.120 |
Why?
| | Sarcoma, Ewing | 1 | 2017 | 102 | 0.120 |
Why?
| | Transplantation Conditioning | 1 | 2017 | 186 | 0.120 |
Why?
| | Immunophenotyping | 1 | 2017 | 322 | 0.120 |
Why?
| | Mass Screening | 1 | 2025 | 1347 | 0.120 |
Why?
| | Drug Synergism | 1 | 2017 | 357 | 0.120 |
Why?
| | Cohort Studies | 3 | 2025 | 5960 | 0.120 |
Why?
| | Apoptosis | 3 | 2019 | 2430 | 0.120 |
Why?
| | Pyrimidines | 1 | 2019 | 532 | 0.120 |
Why?
| | Flow Cytometry | 1 | 2019 | 1173 | 0.110 |
Why?
| | Outpatients | 1 | 2019 | 442 | 0.110 |
Why?
| | Signal Transduction | 2 | 2021 | 5226 | 0.110 |
Why?
| | Cell Proliferation | 3 | 2017 | 2496 | 0.110 |
Why?
| | Seizures | 1 | 2018 | 460 | 0.110 |
Why?
| | Genetic Testing | 1 | 2017 | 478 | 0.110 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 688 | 0.110 |
Why?
| | Immunotherapy, Adoptive | 1 | 2018 | 337 | 0.110 |
Why?
| | Feasibility Studies | 1 | 2019 | 1095 | 0.110 |
Why?
| | Retrospective Studies | 5 | 2025 | 17066 | 0.100 |
Why?
| | Excitatory Amino Acid Agonists | 1 | 2014 | 42 | 0.100 |
Why?
| | NF-kappa B | 1 | 2017 | 661 | 0.100 |
Why?
| | Neuropsychological Tests | 2 | 2023 | 1134 | 0.100 |
Why?
| | Brain Stem | 1 | 2014 | 95 | 0.100 |
Why?
| | MicroRNAs | 1 | 2019 | 701 | 0.090 |
Why?
| | Kidney Neoplasms | 1 | 2017 | 412 | 0.090 |
Why?
| | Nuclear Proteins | 1 | 2017 | 748 | 0.090 |
Why?
| | Histones | 1 | 2018 | 669 | 0.090 |
Why?
| | Phenotype | 2 | 2024 | 3162 | 0.090 |
Why?
| | Glutamic Acid | 1 | 2014 | 251 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2017 | 11679 | 0.090 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2014 | 215 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2015 | 780 | 0.080 |
Why?
| | Skin Neoplasms | 1 | 2017 | 847 | 0.080 |
Why?
| | Animals | 7 | 2025 | 38058 | 0.080 |
Why?
| | DNA Copy Number Variations | 2 | 2021 | 183 | 0.080 |
Why?
| | Cognition Disorders | 1 | 2012 | 538 | 0.070 |
Why?
| | Hippocampus | 1 | 2014 | 965 | 0.070 |
Why?
| | Young Adult | 3 | 2021 | 14105 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2021 | 1455 | 0.070 |
Why?
| | Injections, Spinal | 1 | 2026 | 120 | 0.060 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 2025 | 44 | 0.060 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 2025 | 34 | 0.060 |
Why?
| | Aged, 80 and over | 1 | 2018 | 8265 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1266 | 0.060 |
Why?
| | Adult | 2 | 2019 | 40449 | 0.050 |
Why?
| | Neurons | 1 | 2014 | 1640 | 0.050 |
Why?
| | Child, Hospitalized | 1 | 2025 | 54 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3863 | 0.050 |
Why?
| | Computer Simulation | 2 | 2021 | 1025 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2024 | 307 | 0.050 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 13 | 0.050 |
Why?
| | Tertiary Care Centers | 1 | 2025 | 189 | 0.050 |
Why?
| | Fluorescein Angiography | 1 | 2025 | 189 | 0.050 |
Why?
| | Intelligence Tests | 1 | 2023 | 56 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2637 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2026 | 5408 | 0.050 |
Why?
| | Epigenesis, Genetic | 2 | 2019 | 684 | 0.050 |
Why?
| | Cranial Irradiation | 1 | 2023 | 85 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 1782 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2025 | 241 | 0.050 |
Why?
| | Tomography, Optical Coherence | 1 | 2025 | 271 | 0.050 |
Why?
| | Visual Acuity | 1 | 2025 | 489 | 0.040 |
Why?
| | Gene Ontology | 1 | 2021 | 53 | 0.040 |
Why?
| | Survival Rate | 1 | 2026 | 2089 | 0.040 |
Why?
| | Autophagosomes | 1 | 2021 | 20 | 0.040 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2021 | 191 | 0.040 |
Why?
| | Autophagy-Related Proteins | 1 | 2021 | 46 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2021 | 307 | 0.040 |
Why?
| | Lysosomes | 1 | 2021 | 128 | 0.040 |
Why?
| | Phosphorylation | 2 | 2015 | 1732 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2025 | 1030 | 0.040 |
Why?
| | Chromosomes, Human, Pair 2 | 1 | 2019 | 28 | 0.040 |
Why?
| | Viral Load | 1 | 2021 | 526 | 0.040 |
Why?
| | Incidence | 1 | 2025 | 2879 | 0.040 |
Why?
| | Oncogenes | 1 | 2019 | 119 | 0.040 |
Why?
| | Injections, Intraventricular | 1 | 2018 | 56 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 2019 | 192 | 0.030 |
Why?
| | Aged | 1 | 2018 | 25913 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2020 | 1054 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2018 | 191 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2019 | 372 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2018 | 170 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2019 | 339 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2019 | 318 | 0.030 |
Why?
| | Benzodiazepinones | 1 | 2016 | 18 | 0.030 |
Why?
| | Genes, myc | 1 | 2016 | 50 | 0.030 |
Why?
| | DNA Methylation | 1 | 2021 | 681 | 0.030 |
Why?
| | Cell Cycle | 1 | 2019 | 596 | 0.030 |
Why?
| | Radiotherapy | 1 | 2017 | 206 | 0.030 |
Why?
| | Urea | 1 | 2016 | 84 | 0.030 |
Why?
| | Thiophenes | 1 | 2016 | 128 | 0.030 |
Why?
| | Middle Aged | 1 | 2018 | 35875 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2017 | 383 | 0.030 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2015 | 87 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 769 | 0.030 |
Why?
| | Hospitalization | 1 | 2025 | 2433 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 334 | 0.030 |
Why?
| | Beclin-1 | 1 | 2014 | 11 | 0.030 |
Why?
| | Autophagy-Related Protein 7 | 1 | 2014 | 13 | 0.030 |
Why?
| | Pepstatins | 1 | 2014 | 4 | 0.030 |
Why?
| | Ubiquitin-Activating Enzymes | 1 | 2014 | 20 | 0.030 |
Why?
| | Sequestosome-1 Protein | 1 | 2014 | 15 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2015 | 148 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 965 | 0.030 |
Why?
| | Leucine | 1 | 2014 | 116 | 0.020 |
Why?
| | Protease Inhibitors | 1 | 2014 | 102 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 186 | 0.020 |
Why?
| | Heat-Shock Proteins | 1 | 2014 | 138 | 0.020 |
Why?
| | Mice | 2 | 2025 | 18339 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 427 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2024 | 6429 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1257 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2182 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2025 | 2310 | 0.020 |
Why?
| | Tumor Burden | 1 | 2014 | 319 | 0.020 |
Why?
| | Microtubule-Associated Proteins | 1 | 2014 | 196 | 0.020 |
Why?
| | Pyrazoles | 1 | 2016 | 509 | 0.020 |
Why?
| | Prospective Studies | 1 | 2025 | 7990 | 0.020 |
Why?
| | Monocytes | 1 | 2015 | 538 | 0.020 |
Why?
| | Mice, Nude | 1 | 2014 | 682 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2015 | 509 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 476 | 0.020 |
Why?
| | Doxorubicin | 1 | 2014 | 397 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1821 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2014 | 635 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2014 | 902 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2014 | 477 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2014 | 928 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2363 | 0.020 |
Why?
| | Risk Factors | 1 | 2025 | 10779 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2608 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4271 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2014 | 1166 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 2061 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2014 | 4154 | 0.010 |
Why?
| | Rats | 1 | 2014 | 5597 | 0.010 |
Why?
|
|
Mulcahy Levy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|